Takasago International Corporation
Notice Regarding Tender Offer Application and Recognition of Extraordinary Profit (Forecast)
Takasago International Corporation applied for the tender offer for 420,534 shares of Hisamitsu Pharmaceutical Co., Inc. at 6,082 yen per share, totaling 2,557 million yen, and expects to record an extraordinary profit of 2,408 million yen in the fiscal year ending March 2026.
Key Figures
- Number of shares applied: 420,534 shares (entire holding)
- Planned purchase price: 6,082 yen / share
- Expected recognition of extraordinary profit: 2,408 million yen (Fiscal Year ending March 2026)
AI要約
Overview of Tender Offer Application
Takasago International Corporation's Board of Directors resolved to apply its entire holding of 420,534 common shares of Hisamitsu Pharmaceutical Co., Inc. to the tender offer conducted by Taiyo Kosan Co., Ltd. The planned purchase price is 6,082 yen per share, with a total planned sale amount of 2,557 million yen. The application decision is based on the endorsement of the tender offer by Hisamitsu Pharmaceutical Co., Inc.'s Board of Directors and the reasonableness of the conditions.
Outlook and Impact
If this tender offer is successful and all shares are sold, Takasago International Corporation expects to record an extraordinary profit of 2,408 million yen as investment securities sale gains in both standalone and consolidated financial results for the fiscal year ending March 2026. The tender offer period is from January 7, 2026, to February 19, 2026, with the settlement start date on February 27.
